Search
  • Within this site
AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.
Back to search results

Genetic Test for Equine Immune-Mediated Myositis


Technology Benefits

Identified genetic mutation


Technology Application

Genetic testing for horse susceptibility to IMM and nonexertional rhabdomyolysis Diagnosis of IMM in Quarter Horses, Paint Horses and related breeds


Detailed Technology Description

Immune-mediated myositis (IMM) is a disorder in which the immune system attacks skeletal muscles, causing rapid atrophy of the muscle tissue. IMM is predominantly found in American Quarter Horses and is characterized by rapid-onset muscle atrophy often causing wasting of 40% of the mass of the topline muscles in a matter of days. IMM is responsive to treatment with corticosteroids to halt muscle wasting with return of muscle mass over months. Current diagnosis of IMM in horses involves the measurement of serum creatine kinase and aspartate transaminase, with a definitive diagnosis requiring biopsies of the atrophied rump/back muscles. Researchers at the University of California, Davis and Michigan State University have discovered the genetic mutation for immune-mediate myositis in breeds related to the American Quarter Horse and have created a genetic test for this disease. Horses that are homozygous or heterozygous for the mutation may develop IMM or severe nonexertional rhabdomyolysis. The disease is often triggered by environmental factors such as infection or vaccination in genetically susceptible horses. The mutation is highly associated with the IMM phenotype and can be used with related breeds.This test can be used in breeding stock to minimize the occurrence of IMM.


Others

Tech ID/UC Case

29366/2017-280-0


Related Cases

2017-280-0


Country/Region

USA

For more information, please click Here
Business of IP Asia Forum
Desktop View